Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.79 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5112511 | 0.88 | KCNH2 (1.00) | KCNH2TLR9TLR8TLR7 | |
| SCHEMBL5111576 | 0.81 | KCNH2 (0.56) | KCNH2CHRNA7TLR9TLR8TLR7 | |
| SCHEMBL5109569 | 0.80 | KCNH2 (0.61) | KCNH2TLR9TLR8TLR7 | |
| SCHEMBL5107232 | 0.70 | KCNH2 (0.50) | KCNH2CHRNA7TLR9TLR8TLR7 | |
| SCHEMBL9718617 | 0.69 | KCNH2 (0.65) | KCNH2 | |
| SCHEMBL5113463 | 0.68 | KCNH2 (1.00) | KCNH2 | |
| SCHEMBL14218960 | 0.68 | KCNH2 (0.69) | KCNH2 | |
| SCHEMBL5112482 | 0.68 | KCNH2 (0.69) | KCNH2 | |
| SCHEMBL9369083 | 0.68 | CHRM2 (0.46) | KCNH2TLR9TLR8TLR7CHRM2 | |
| SCHEMBL873067 | 0.66 | CHRNA7 (0.79) | CHRNA7CHRM2CHRM4CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080103170-A1 | Nicotinic Acetylcholine Receptor Ligands | ASTRAZENECA AB (SE) | 2008-05-01 | — | — | US | claimed |
| EP-1831212-A1 | NICOTINIC ACETYCHOLINE RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | claimed |
| WO-2006065217-A1 | NICOTINIC ACETYCHOLINE RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | claimed |
| US-20080103170-A1 | Nicotinic Acetylcholine Receptor Ligands | ASTRAZENECA AB (SE) | 2008-05-01 | — | — | US | disclosed |
| US-20080103170-A1 | Nicotinic Acetylcholine Receptor Ligands | ASTRAZENECA AB (SE) | 2008-05-01 | — | — | US | disclosed |
| US-20080103170-A1 | Nicotinic Acetylcholine Receptor Ligands | ASTRAZENECA AB (SE) | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103170-A1 | Nicotinic Acetylcholine Receptor Ligands | CHRNG, CHRNE, CHRNA1 | KCNH2 501/4885CHRNA7 7/4885TLR9 1064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.